AbSci

Historical price data

Absci's mission is to create better biologics for patients, faster by overcoming traditional drug discovery bottlenecks. The company has evolved from its synthetic biology roots into an integrated AI biotech, building a proprietary data 'moat' and a closed-loop platform that designs and validates drug candidates in iterative six-week cycles. Its strategy leverages this platform to advance an internal pipeline and forge strategic partnerships, positioning it at the forefront of AI-driven therapeutic design.

The Integrated Drug Creation™ Platform is a closed-loop system combining proprietary high-throughput wet lab data generation, generative AI models for de novo design and optimization, and rapid wet-lab validation in iterative six-week cycles.

Absci differentiates itself through deep integration of a proprietary, high-throughput wet lab, creating a unique 'data moat' and closed-loop system. It competes with integrated AI biotechs (e.g., Recursion), AI software providers (e.g., Schrödinger, Insilico), and large pharma's internal AI efforts, as well as the traditional, slower methods of biologics discovery.